Is spironolactone safe for dialysis patients?

Nephrology Dialysis Transplantation

Volumn 18, Issue 11, 2003, Pages 2364-2368

  Hussain, Shahid ^a   Dreyfus, Darren E ^a   Marcus, Richard J ^a   Biederman, Robert W W ^a   McGill, Rita L ^a,b  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Haemodialysis; Hyperkalaemia; Spironolactone

Indexed keywords

ALDOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM; SPIRONOLACTONE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EPISTAXIS; FEMALE; GYNECOMASTIA; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; LEUKOPENIA; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; STUDENT T TEST; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; FEMALE; HUMANS; HYPERKALEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POTASSIUM; RENAL DIALYSIS; RENIN; SPIRONOLACTONE;

EID: 0242288593     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg413     Document Type: Article

References (19)

1. Collins AJ, Li S, Ma JZ, Herzog CA. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001; 38 [Suppl 1]: S26-S29
2. United States Renal Data System. USRDS 2002 Annual Data Report. United States Department of Health and Human Services. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, April 2002
3. Ritz E, Dikow R, Adamzcak M, Zeier M. Congestive heart failure due to systolic dysfunction: the Cinderella of cardiovascular management in dialysis patients. Semin Dial 2002; 3: 135-140
4. Malanuk RM, Nielsen CD, Theis P, Assey ME, Usher BW, Leman RB. Treatment of coronary artery disease in hemodialysis patients: PTCA vs. stent. Catheter Cardiovasc Interv 2001; 54: 459-465
5. Szczech LA, Reddan DN, Owen WF et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int 2001; 60: 292-299
6. Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002; 106: 2207-2211
7. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990; 82: 1730-1736
8. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995; 76: 1259-1265
9. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997; 35: 30-34
10. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circulation 1990; 67: 1355-1364
11. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25: 563-575
12. Klug D, Robert V, Swynghedauw B. Role of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation. Am J Cardiol 1993; 71: 46A-54A.
13. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study). Am J Cardiol 1996; 78: 902-907
14. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med 1999; 341: 709-717
15. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110: 438-441
16. Vlassopoulos D, Sonikian M, Dardioti V et al. Insulin and mineralocorticoids influence on extrarenal potassium metabolism in chronic hemodialysis patients. Ren Fail 2001; 23: 833-842
17. Sugarman A, Brown RS. The role of aldosterone in potassium tolerance: studies in anephric humans. Kidney Int 1988; 34: 397-403
18. Papadimitriou M, Vyzantiadis A, Milionis A, Memmos D, Metaxas P. The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal transplantation. Life Support Sys 1983; 1: 197-206
19. Schohn DC, Jahn HA, Pelletier BC. Dose-related cardiovascular effects of spironolactone. Am J Cardiol 1993; 71: 40A-50A